Epigenetic suppression of histone methylation reverses age and AD-related cognitive decline
Description: Project Narrative Clinical trials of Alzheimer's disease (AD) therapeutics have had the lowest overall success rate for any major therapeutic area despite 413 trials of 244 compounds during 2002-2012. The lack of efficacy of the current intervention strategies highlights the urgent need for new biological approaches to treat AD that are effective across the complex etiology of AD. This proposal will investigate a novel hypothesis that epigenetic gene repression controlled by the epigenetic mark H3K9me3 imbalances essential pathways for learning and memory, that this gene repression forms the basis for the etiological complexity of AD, and that cognitive function can be restored in AD using a newly developed therapeutic that reduces this epigenetic mark.
Funder: National Institutes of Health
Amount: $3,774,000
Funding type: research
Funder scheme: RF1
Start date: 2018-08-01
End date: 2023-08-31
Investigator: MARCELO ANDRES WOOD
Institution: UNIVERSITY OF CALIFORNIA-IRVINE
Subfield: Molecular Biology
Domain: Life Sciences
Funded outputs count: 17
Funder award ID: 1rf1ag057558-01a1
OpenAlex ID: G478407961